Identification of Recurrently Presented Neoantigens

As these often arise from driver mutations, they are expected to be clonal and recur between patients. To identify new hotspot neoantigens, we developed a data-driven strategy for scanning recurrent neoantigens in melanoma using immunopeptidomics. Using this approach, we have already identified novel MHC-presented neoantigens derived from NRAS^Q61K, NRAS^Q61R, PIK3CA^E545 and KRAS^G12V. Importantly, our identification of the neoantigen cognate TCRs allows for an 'off-the shelf' treatment pan-cancer.

Further reading:

Peri, A. et al. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. J Clin Invest 131 (2021)

Peri, A. et al. The landscape of T cell antigens for cancer immunotherapy. Nat Cancer 4, 937-954 (2023)